|
private:biotherapeutics
|
5336243
|
May 22nd, 2019 12:00AM
|
BioTherapeutics Inc.
|
190
|
6.00
|
Open
|
Biotechnology
|
May 22nd, 2019 05:00PM
|
May 22nd, 2019 05:00PM
|
BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health.
Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.
|
Open
|
|
Open
|
1800 Kraft Drive, 200
|
Blacksburg
|
va
|
US
|
24060
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Mar 18th, 2018 12:00AM
|
BioTherapeutics Inc.
|
148
|
18.00
|
Open
|
Biotechnology
|
Mar 18th, 2018 02:57PM
|
Mar 18th, 2018 02:57PM
|
|
Open
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 17th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 16th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 15th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 14th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 13th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 12th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 11th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
private:biotherapeutics
|
5336243
|
Feb 10th, 2018 12:00AM
|
BioTherapeutics Inc.
|
131
|
15.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
BioTherapeutics (BTI) is a preclinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
|
|
|
|
|
|
|
|
|
|
Biotherapeutics
|
|
Pharmaceuticals & Biotechnology
|